Acacetin (Flavone · Antiarrhythmic Research · Anti-inflammatory)

Compound	Acacetin
Chemical class	Polyphenol — Flavone (4′-Methoxyflavone)
CAS	480-44-4
Primary source	Robinia pseudoacacia (black locust flowers), Turnera diffusa (damiana)
Key applications	Antiarrhythmic (IKur inhibitor), anti-inflammatory, anxiolytic
Claim strength	Moderate
Typical form	Research isolate; damiana extract constituent

Name origin: From Acacia species, where acacetin was first identified as a floral flavone. Traditional use: Acacetin-containing plants — damiana (Turnera diffusa) and black locust (Robinia pseudoacacia) — have traditional use as aphrodisiacs, anxiolytics, and mild stimulants in Mexican and Central American herbal medicine. Research trajectory: Acacetin has attracted significant cardiology research interest as a selective IKur (ultra-rapid delayed rectifier potassium channel) inhibitor relevant to atrial fibrillation management. It also demonstrates anti-inflammatory and weak estrogenic activities. Commercial source: Not widely available as a bulk isolate; accessible as a constituent of damiana leaf extract or as a research-grade standard.

---

Evidence for Acacetin Applications

Antiarrhythmic activity (IKur inhibition): Acacetin selectively inhibits the atrial-specific IKur potassium channel at low micromolar concentrations, with minimal ventricular channel effects. Animal electrophysiology studies show prolongation of atrial refractoriness without QTc prolongation. This mechanism is of pharmaceutical interest for atrial fibrillation, though clinical translation is pending. Claim strength: Moderate (strong preclinical; no human trials).

Anti-inflammatory and NF-κB suppression: Acacetin inhibits LPS-induced NF-κB activation, reducing TNF-α, IL-6, and iNOS in macrophage models. In vivo anti-inflammatory effects demonstrated in murine colitis and peritonitis models. Claim strength: Moderate.

Anxiolytic and sedative effects: Animal studies using acacetin from damiana extract show GABA-A receptor modulation consistent with anxiolytic activity. This aligns with traditional use of damiana for relaxation and mood. Clinical validation is absent. Claim strength: Emerging.

---

Dosage & Formulator Specification

No established human clinical dose for acacetin. Preclinical cardiology studies use intravenous or direct cardiac preparations; oral bioavailability and equivalent human dose is an open research question. Anxiolytic animal models used 10–25 mg/kg oral doses, suggesting significant interspecies extrapolation required.

For formulators using acacetin as a component of damiana extract in adaptogen or relaxation blends, specify damiana leaf extract standardised to 0.5–1% total flavones or acacetin equivalent. Typical damiana extract dose in such formulations: 300–600 mg/day.

Acacetin has low aqueous solubility (logP ~3.0); lipid-based delivery or nanosuspension is preferred for oral bioavailability. Stability at standard processing temperatures is good; avoid alkaline conditions.

---

Frequently Asked Questions — Acacetin

What makes acacetin unique among flavones for cardiology research?
Its selective IKur inhibition distinguishes acacetin from non-selective ion channel modulators. IKur is expressed almost exclusively in atrial tissue, making acacetin a candidate for atrium-selective antiarrhythmic therapy without ventricular proarrhythmic risk — a gap in current AF pharmacology.

Can acacetin be included in a heart health supplement?
Given the absence of human clinical data and the pharmaceutical nature of its primary mechanism (IKur inhibition), acacetin is not appropriate for supplement-level cardiovascular claims at this stage. It may be referenced as a botanical constituent with emerging research interest.

Is damiana extract the best commercial source of acacetin?
Damiana (Turnera diffusa) leaf extract is the most accessible botanical source for supplement use. Black locust (Robinia pseudoacacia) flower extract is also acacetin-rich but is less commercially established as a supplement ingredient.

Does acacetin have estrogenic activity?
Weak ERβ agonism has been reported in vitro. This may contribute to traditional aphrodisiac properties attributed to damiana. The estrogenic potency is low relative to established phytoestrogens such as genistein; clinical significance at supplement doses is unlikely but should be noted for hormone-sensitive populations.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery